Intellia Therapeutics Stock Buy Hold or Sell Recommendation
| NTLA Stock | USD 15.21 0.48 3.26% |
Given the investment horizon of 90 days and your below-average risk tolerance, our recommendation regarding Intellia Therapeutics is 'Strong Sell'. Macroaxis provides Intellia Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NTLA positions.
Check out Intellia Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide. In addition, we conduct extensive research on individual companies such as Intellia and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Intellia |
Execute Intellia Therapeutics Buy or Sell Advice
The Intellia recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Intellia Therapeutics. Macroaxis does not own or have any residual interests in Intellia Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Intellia Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Intellia Therapeutics Trading Alerts and Improvement Suggestions
| Intellia Therapeutics generated a negative expected return over the last 90 days | |
| Intellia Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 36.27 M. Net Loss for the year was (481.19 M) with loss before overhead, payroll, taxes, and interest of (367.86 M). | |
| Intellia Therapeutics currently holds about 874.28 M in cash with (394.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.5. | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Intellia Therapeutics SWOT analysis gene editing firms stock faces pivotal trials |
Intellia Therapeutics Returns Distribution Density
The distribution of Intellia Therapeutics' historical returns is an attempt to chart the uncertainty of Intellia Therapeutics' future price movements. The chart of the probability distribution of Intellia Therapeutics daily returns describes the distribution of returns around its average expected value. We use Intellia Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Intellia Therapeutics returns is essential to provide solid investment advice for Intellia Therapeutics.
| Mean Return | -0.52 | Value At Risk | -7.15 | Potential Upside | 5.01 | Standard Deviation | 4.36 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Intellia Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Intellia Stock Institutional Investors
| Shares | Contrarius Investment Management Ltd | 2024-09-30 | 2 M | Casdin Capital, Llc | 2024-09-30 | 2 M | Alliancebernstein L.p. | 2024-06-30 | 1.8 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-06-30 | 1.3 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.2 M | Himension Fund | 2024-06-30 | 1 M | Citadel Advisors Llc | 2024-09-30 | 989.4 K | Two Sigma Investments Llc | 2024-09-30 | 980.4 K | Ark Investment Management Llc | 2024-09-30 | 12.3 M | Vanguard Group Inc | 2024-09-30 | 9.6 M |
Intellia Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (1.6M) | 107.4M | (39.1M) | 410.0M | (295.1M) | (280.4M) | |
| Free Cash Flow | (110.0M) | (53.5M) | (237.8M) | (391.7M) | (408.1M) | (387.7M) | |
| Depreciation | 5.6M | 6.3M | 6.9M | 7.6M | 9.0M | 4.9M | |
| Other Non Cash Items | (3.7M) | 573K | 2.9M | 95.8M | (3.5M) | (3.3M) | |
| Capital Expenditures | 6.8M | 3.6M | 12.8M | 58.4M | 14.0M | 13.3M | |
| Net Income | (99.5M) | (134.2M) | (267.9M) | (474.2M) | (481.2M) | (457.1M) | |
| End Period Cash Flow | 57.2M | 164.6M | 125.5M | 535.5M | 240.4M | 207.5M | |
| Change To Netincome | 15.1M | 19.9M | 45.7M | 171.8M | 197.6M | 207.4M | |
| Investments | 32.0M | (210.9M) | (535.0M) | 160.3M | (107.4M) | (112.8M) | |
| Change To Inventory | 1.7M | 4.9M | 7.8M | (19.5M) | (17.6M) | (16.7M) | |
| Change Receivables | 2.9M | 2.5M | 99K | (1.7M) | (2.0M) | (1.9M) |
Intellia Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Intellia Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Intellia Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Intellia stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.86 | |
β | Beta against Dow Jones | 2.84 | |
σ | Overall volatility | 4.41 | |
Ir | Information ratio | -0.15 |
Intellia Therapeutics Volatility Alert
Intellia Therapeutics exhibits very low volatility with skewness of -1.55 and kurtosis of 5.47. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Intellia Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Intellia Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Intellia Therapeutics Fundamentals Vs Peers
Comparing Intellia Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Intellia Therapeutics' direct or indirect competition across all of the common fundamentals between Intellia Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Intellia Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Intellia Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Intellia Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Intellia Therapeutics to competition |
Note: Disposition of 2012 shares by Dube Michael P of Intellia Therapeutics at 19.01 subject to Rule 16b-3 [view details]
Intellia Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Intellia . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Intellia Therapeutics Buy or Sell Advice
When is the right time to buy or sell Intellia Therapeutics? Buying financial instruments such as Intellia Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Intellia Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run ISP Thematic Idea Now
ISP
Internet Service Providers (ISP) companies and IT providers specializing in internet technologies. The ISP theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ISP Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Intellia Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.449 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.